Daivobet once daily versus twice daily for the treatment of Psoriasis vulgaris

Short communication


Mohamed Elhashme, Ali El- Zurghani, Khairi Elgaed, Bashir Zendah and Mohamed Benghazil

Al-Fatah University – Tripoli Medical Centre, Tripoli – Libya

JMJ Vo1.6 No.1 (Autumn) 2006: 66-68


Combination therapy is being used with increasing frequency in the treatment of psoriasis in order to improve the efficacy and reduce side effects. Daivobet is the best example combining the effect of calcipotriol and betamethasone dipropionate. Eighty-three patients diagnosed as mild to moderate psoriasis vulgaris were enrolled in the study. They were divided into two groups. The first group of 47 patients were instructed to apply daivobet once daily, the other group of 36 patients applied daivobet twice daily. Psoriasis area and severity index (PASI), was used for evaluation of the response to treatment, after 2, 3, and 4 weeks. The reduction in PASI score at the end of the study was statistically significant for both groups ( p-value < 0.0001 for both groups ). There was no significant statistical difference regarding efficacy between once daily or twice daily application. In conclusion: We recommend once daily application of topical combination therapy of calcipotriol and betamethazone dipropionate for the treatment of mild to moderate psoriasis, which is efficacious with less side effects. Keywords: Daivobet, Calcipotriol, Betamethasone dipropionate, PASI score Link/DOI: http://www.jmj.org.ly/modules.php?name=News&file=article&sid=1168